<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03290950</url>
  </required_header>
  <id_info>
    <org_study_id>17-352</org_study_id>
    <nct_id>NCT03290950</nct_id>
  </id_info>
  <brief_title>A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to test the safety and effectiveness of the study drug, daratumumab in&#xD;
      combination with carfilzomib, lenalidomide and dexamethasone. The purpose of this study is to&#xD;
      test whether giving daratumumab along with the other drugs (carfilzomib, lenalidomide and&#xD;
      dexamethasone) is safe for patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 25, 2017</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase II study and treated with 4-drug combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assess the rate of MRD negativity</measure>
    <time_frame>2 years</time_frame>
    <description>Patients with ≤ PR after completing 4 cycles will be included in the analysis of the primary objective and will be considered MRD positive. Patients who receive any study drug and have at least one post-baseline disease assessment will be considered evaluable for the primary endpoint.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daratumumab</intervention_name>
    <description>Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carfilzomib</intervention_name>
    <description>Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, 16 and 22; Cycles 3-4: Dexamethasone 20mg/dose, days 1,2,8,9,15 and 16, Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Cohort 1 administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 1, 2, 22; 40 mg/dose days 8 and 15, Cycles 2: Dexamethasone 40mg/dose, days 1, 8, 15; 20 mg/dose day 22, Cycles 3-4: Dexamethasone 40mg/dose, Days 1, 8 15, Cycles 5-8: Dexamethasone 20mg/dose, Days 1, 8, 15</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Cohort 2 administration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed patients with histologically confirmed MM based on the following&#xD;
             criteria:&#xD;
&#xD;
               -  Clonal plasma cells in the bone marrow&#xD;
&#xD;
               -  Measurable disease within the past 4 weeks defined by any one of the following:&#xD;
&#xD;
               -  Serum monoclonal protein ≥ 1.0 g/dL&#xD;
&#xD;
               -  Urine monoclonal protein &gt;200 mg/24 hour&#xD;
&#xD;
               -  Involved serum immunoglobulin free light chain &gt; 10 mg/dL AND abnormal&#xD;
                  kappa/lambda ratio&#xD;
&#xD;
          -  Evidence of underlying end organ damage and/or myeloma defining event attributed to&#xD;
             underlying plasma cell proliferative disorder meeting at least one of the following:&#xD;
&#xD;
               -  Hypercalcemia: serum calcium &gt;0.25 mmol/L (&gt; 1 mg/dL) above upper limit of normal&#xD;
                  or ≥ 2.75 mmol/L (11 mg/dL)&#xD;
&#xD;
               -  Anemia: hemoglobin value &lt;10 g/dL or &gt; 2 g/dL below lower limit of normal&#xD;
&#xD;
               -  Bone disease: ≥ 1 lytic lesions on skeletal X-ray, CT, or PET-CT. For patients&#xD;
                  with 1 lytic lesion, bone marrow should demonstrate ≥10% clonal plasma cells&#xD;
&#xD;
               -  Clonal bone marrow plasma cell percentage ≥60%&#xD;
&#xD;
               -  Involved/un-involved serum free light chain ratio ≥100 and involved free light&#xD;
                  chain &gt;100 mg/L.&#xD;
&#xD;
                    -  1 focal lesion on magnetic resonance imaging study (lesion must be &gt;5 mm) in&#xD;
                       size&#xD;
&#xD;
          -  Creatinine Clearance ≥ 60 ml/min. CrCl can be measured or estimated using&#xD;
             Cockcroft-Gault method, MDRD, or CKD-EPI formulae&#xD;
&#xD;
          -  Age ≥ 18 years at the time of signing the informed consent documentation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Absolute neutrophil&#xD;
             count (ANC) ≥ 1.0 K/uL, hemoglobin ≥ 8 g/dL, and platelet count ≥ 75 K/uL, unless if&#xD;
             cytopenias are deemed to be due disease at discretion of clinical investigator.&#xD;
             Transfusions and growth factors are permissible.&#xD;
&#xD;
          -  Adequate hepatic function, with bilirubin &lt; 1.5 x the ULN, and AST and ALT &lt; 3.0 x&#xD;
             ULN.&#xD;
&#xD;
          -  All study participants must be able to tolerate one of the following&#xD;
             thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin&#xD;
             (coumadin) or alternative anti-coagulant.&#xD;
&#xD;
          -  All study participants must be registered into the mandatory eREMS® program, and be&#xD;
             willing and able to comply with the requirements of REMS®.&#xD;
&#xD;
          -  Females of childbearing potential (FCBP)† must have a negative serum or urine&#xD;
             pregnancy test within 10 - 14 days and again within 24 hours prior to prescribing&#xD;
             lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either&#xD;
             commit to continued abstinence from heterosexual intercourse or begin TWO acceptable&#xD;
             methods of birth control, one highly effective method and one additional effective&#xD;
             method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP&#xD;
             must also agree to ongoing pregnancy testing. Men must agree to use a latex condom&#xD;
             during sexual contact with a FCBP even if they have had a successful vasectomy.&#xD;
&#xD;
               -  A female of childbearing potential is a sexually mature female who: 1) has not&#xD;
                  undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally&#xD;
                  postmenopausal for at least 24 consecutive months (i.e., has had menses at any&#xD;
                  time in the preceding 24 consecutive months).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving &gt;1 cycle of prior treatment or concurrent systemic treatment for&#xD;
             multiple myeloma&#xD;
&#xD;
               -  Treatment of hypercalcemia or spinal cord compression or aggressively progressing&#xD;
                  myeloma with current or prior corticosteroids is permitted&#xD;
&#xD;
               -  Bisphosphonates are permitted&#xD;
&#xD;
               -  Concurrent or prior treatment with corticosteroids for indications other than&#xD;
                  multiple myeloma is permitted&#xD;
&#xD;
               -  Prior treatment with radiotherapy is permitted&#xD;
&#xD;
               -  Prior treatment for smoldering myeloma is permitted with a washout period of 2&#xD;
                  weeks from last dose. Smoldering patients previously treated with carfilzomib are&#xD;
                  excluded.&#xD;
&#xD;
               -  Patients with measurable disease who received up to one cycle of any therapy&#xD;
                  within 60 days with a washout period of 2 weeks from last dose (on a trial or&#xD;
                  outside a trial) are eligible&#xD;
&#xD;
          -  Plasma cell leukemia&#xD;
&#xD;
          -  POEMS syndrome&#xD;
&#xD;
          -  Amyloidosis&#xD;
&#xD;
          -  Has known chronic obstructive pulmonary disease with a forced expiratory volume in 1&#xD;
             second (FEV1) &lt;50% of predicted normal (note that FEV1 testing is required for&#xD;
             subjects suspected of having chronic obstructive pulmonary disease and subjects must&#xD;
             be excluded if FEV1 &lt;50% of predicted normal).&#xD;
&#xD;
          -  Pregnant or lactating females. Because there is a potential risk for adverse events&#xD;
             nursing infants secondary to treatment of the mother with carfilzomib in combination&#xD;
             with lenalidomide. These potential risks may also apply to other agents used in this&#xD;
             study.&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes&#xD;
&#xD;
          -  Active hepatitis B or C infection&#xD;
&#xD;
          -  Subject is:&#xD;
&#xD;
               -  Seropositive for human immunodeficiency virus (HIV)&#xD;
&#xD;
               -  Seropositive for hepatitis B (defined by a positive test for hepatitis B surface&#xD;
                  antigen [HBsAg]). Subjects with resolved infection (i.e., subjects who are HBsAg&#xD;
                  negative but positive for antibodies to hepatitis B core antigen [anti-HBc]&#xD;
                  and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened&#xD;
                  using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus&#xD;
                  (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION:&#xD;
                  Subjects with serologic findings suggestive of HBV vaccination (anti-HBs&#xD;
                  positivity as the only serologic marker) AND a known history of prior HBV&#xD;
                  vaccination, do not need to be tested for HBV DNA by PCR.*&#xD;
&#xD;
               -  Seropositive for hepatitis C (except in the setting of a sustained virologic&#xD;
                  response [SVR], defined as aviremia at least 12 weeks after completion of&#xD;
                  antiviral therapy).&#xD;
&#xD;
          -  Has significant cardiovascular disease with NYHA Class III or IV symptoms, EF&lt;40% or&#xD;
             hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction&#xD;
             within 6 months prior to enrollment, or unstable angina, or unstable arrhythmia as&#xD;
             determined by history and physical examination. Echocardiogram will be performed&#xD;
             during screening evaluation.&#xD;
&#xD;
          -  Pulmonary hypertension&#xD;
&#xD;
          -  Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease,&#xD;
             or bowel resection that would prevent absorption of oral agents&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including but not limited to active infection or&#xD;
             psychiatric illness/social situations that would compromise compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Significant neuropathy ≥Grade 3 or Grade 2 neuropathy with pain at baseline&#xD;
&#xD;
          -  Contraindication to any concomitant medication, including antivirals or&#xD;
             anticoagulation.&#xD;
&#xD;
          -  Major surgery within 3 weeks prior to first dose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neha Korde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Daratumumab</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>17-352</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

